(2R,4R,5R)-5-[(2-aminoacetyl)amino]-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,4R,5R)-5-[(2-aminoacetyl)amino]-2,4-dihydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
• 化学式: C₁₁H₂₀N₂O₉
• 分子量: 324.28
• InChiKey: FJXPWVIFADLJQN-HLLNYCDZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.7
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  203
• 氢给体数：
  8
• 氢受体数：
  10

文献信息

• Coagulation Factor IX Conjugates
  申请人：Novo Nordisk A/S

  公开号：US20150225710A1

  公开（公告）日：2015-08-13

  The present invention relates to Factor IX polypeptides conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used—for example—in the treatment or prevention of bleeding disorders such as haemophilia B.

  本发明涉及将Factor IX多肽与Heparosan（HEP）聚合物结合的方法，制造方法以及这种结合物的用途。所得到的结合物可以用于治疗或预防出血性疾病，如血友病B。
• Factor VIII Conjugates
  申请人：Novo Nordisk A/S

  公开号：US20160120953A1

  公开（公告）日：2016-05-05

  The present invention relates to FVIII conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia.

  本发明涉及到与肝素硫酸聚合物（HEP）共轭的FVIII，其制造方法以及这种共轭物的用途。所得的共轭物可以用于治疗或预防出血性疾病，如血友病。
• Factor VII Conjugates
  申请人：NOVO NORDISK A/S

  公开号：US20150225711A1

  公开（公告）日：2015-08-13

  The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorder
• THROMBIN SENSITIVE COAGULATION FACTOR X MOLECULES
  申请人：NOVO NORDISK A/S

  公开号：US20160024487A1

  公开（公告）日：2016-01-28

  The present invention relates to thrombin sensitive coagulation Factor X (FX), as well as use thereof in medicine. In particular the invention relates to FX molecules comprising 2 to 10 amino acid modifications in the activation peptide N-terminally of the FX “IVGG” motif as well as compositions comprising such molecules and use thereof. Such molecules may be useful in connection with convenient and patient friendly treatment regimens in treatment and prophylaxis of haemophilia.
• [EN] THROMBIN SENSITIVE COAGULATION FACTOR X MOLECULES<br/>[FR] MOLÉCULES DE FACTEUR DE COAGULATION X SENSIBLE À LA THROMBINE
  申请人：NOVO NORDISK AS

  公开号：WO2014140103A2

  公开（公告）日：2014-09-18

  The present invention relates to thrombin sensitive coagulation Factor X (FX), as well as use thereof in medicine. In particular the invention relates to FX molecules comprising 2 to 10 amino acid modifications in the activation peptide N-terminally of the FX "IVGG" motif as well as compositions comprising such molecules and use thereof. Such molecules may be useful in connection with convenient and patient friendly treatment regimens in treatment and prophylaxis of haemophilia.